首页 蛋白库 基因库 产品 会员服务
位置：首页 > 产品库 > ZM 241385
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
ZM 241385
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
ZM 241385图片
CAS NO:139180-30-6
包装与价格：
包装价格(元)
50mg询价
10mg询价

ZM 241385 是一种有效的、高亲和力的选择性腺苷 A2a 受体 (A2AR) 拮抗剂，Ki 值为 1.4 nM。
Cas No.139180-30-6
化学名4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)ethyl)phenol
Canonical SMILESOC1=CC=C(C=C1)CCNC2=NC3=NC(C4=CC=CO4)=NN3C(N)=N2
分子式C16H15N7O2
分子量337.34
溶解度DMSO: 100mM,Ethanol: 5 mM
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
文献引用
产品描述

ZM241385 is a potent, high affinity and selective adenosine A2a receptor (A2AR) antagonist with a Ki value of 1.4 nM[1][2][3].

ZM241385 (1 μM; 24 hours; PC12 cells) treatment reverses the phenomenon that A2AR agonist CGS21680 significantly upregulates A2AR mRNA levels[1].ZM241385 (1 μM; 48 hours; PC12 cells) treatment reverses the phenomenon that A2AR agonist CGS21680 significantly increases A2AR protein levels[1].

ZM241385 (0.2 μg/mouse, 0.4 μg/mouse; intraperitoneal injection; every day; for 11 weeks; female C57BL/6 WT mice) treatment decreases tumor volume, activates CD8+ T cells and reduces the frequency of splenic MDSC[4].

References:
[1]. Wang Z, et al. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drugcandidate ZM241385. PLoS One. 2010 Nov 8;5(11):e13883. doi: 10.1371/journal.pone.0013883.
[2]. Linden J, et al. Characterization of human A(2B) adenosine receptors: radioligandbinding, western blotting, and coupling to G(q) in human embryonickidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13.
[3]. Poucher SM, et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosinereceptor antagonist. Br J Pharmacol. 1995 Jul;115(6):1096-102.
[4]. Ludwig S, et al. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. Cancer Immunol Immunother. 2019 Jul;68(7):1133-1141.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2025